Scholar Rock Holding (SRRK) Receivables - Other (2022 - 2026)
Scholar Rock Holding (SRRK) posted quarterly Receivables - Other of $2.8 million for Q1 2026, up 46.35% year-over-year from $1.9 million in Q1 2025, and up 1.64% quarter-over-quarter from $2.8 million in Q4 2025.
Scholar Rock Holding (SRRK) Receivables - Other (2022 - 2026) Analysis & Trends
Scholar Rock Holding's Receivables - Other history runs 5 years deep, the most recent figure standing at $2.8 million for Q1 2026.
- In Q1 2026, Receivables - Other rose 46.35% year-over-year to $2.8 million; the TTM figure through Mar 2026 stood at $2.8 million (up 46.35% YoY), while the FY2025 annual figure was $2.8 million, up 30.13% from the prior year.
- Receivables - Other for Q1 2026 stood at $2.8 million, up from $2.8 million in the prior quarter.
- The five-year high for Receivables - Other was $3.5 million in Q3 2025, with the low at $1.1 million in Q4 2023.
- The 5-year median for Receivables - Other is $2.0 million (2025), against an average of $2.1 million.
- The sharpest annual moves came in 2023 and 2025: Receivables - Other slumped 60.66% in 2023, then surged 216.88% in 2025.
- Scholar Rock Holding's Receivables - Other stood at $2.7 million in 2022, then plunged by 60.66% to $1.1 million in 2023, then jumped by 99.91% to $2.2 million in 2024, then surged by 30.13% to $2.8 million in 2025, then climbed by 1.64% to $2.8 million in 2026.
- Business Quant data shows SRRK's Receivables - Other at $2.8 million in Q1 2026, $2.8 million in Q4 2025, and $3.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Scholar Rock Holding | 6.39 Bn | 6.39 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.96 Mn |
| Jun 30, 2026 | 1.96 Mn |
| Mar 31, 2026 | 2.85 Mn |
| Mar 31, 2026 | 2.85 Mn |
| Dec 31, 2025 | 2.80 Mn |
| Dec 31, 2025 | 2.80 Mn |
| Sep 30, 2025 | 3.55 Mn |
| Sep 30, 2025 | 3.55 Mn |
| Jun 30, 2025 | 1.97 Mn |
| Jun 30, 2025 | 1.97 Mn |
| Mar 31, 2025 | 1.94 Mn |
| Mar 31, 2025 | 1.94 Mn |
| Dec 31, 2024 | 2.15 Mn |
| Dec 31, 2024 | 2.15 Mn |
| Sep 30, 2024 | 1.12 Mn |
| Sep 30, 2024 | 1.12 Mn |
| Jun 30, 2024 | 1.29 Mn |
| Jun 30, 2024 | 1.29 Mn |
| Mar 31, 2024 | 1.12 Mn |
| Mar 31, 2024 | 1.12 Mn |